

## Author Index (Vol. 93)

- Alberti, K.G.M., see Winocour, P.H. (93) 71  
Aliev, G., see Cirillo, R. (93) 133  
Anderson, D.C., see Winocour, P.H. (93) 83  
Angelini, G.D., see Francis, S.E. (93) 155  
Archbold, P., see Murphy, B.G. (93) 53  
Arrol, S., see Tames, F.J. (93) 237  
Arrol, S., see Winocour, P.H. (93) 83  
Aviram, M., see Hoffman, R. (93) 105
- Balanya, J., see Vilella, E. (93) 145  
Barcew-Wiszniwska, B., see Wójcicki, J. (93) 7  
Bernini, F., see Corsini, A. (93) 95  
Bhatnagar, D., see Winocour, P.H. (93) 83  
Bihari-Varga, M., see Landi, A. (93) 17  
Blache, D., Bouthillier, D. and Davignon, J.  
Acute influence of smoking on platelet behaviour,  
endothelium and plasma lipids and normalization by Aspirin  
(93) 179  
Blann, A.D. and McCollum, C.N.  
Hemostatic risk factors in patients with vascular disease (93)  
255  
Bogers, A.J.J., see Slomp, J. (93) 25  
Bosman, F., see Span, A.H.M. (93) 41  
Bouthillier, D., see Blache, D. (93) 179  
Brook, G.J., see Hoffman, R. (93) 105  
Bruggeman, C.A., see Span, A.H.M. (93) 41  
Bueno, M., see Sarria, A. (93) 157
- Capdevila, C., see Gabaldón, M. (93) 217  
Catapano, A.L., see Corsini, A. (93) 95  
Cercek, B., see Khorsandi, M. (93) 115  
Cirillo, R., Aliev, G., Italiano, G. and Prosdocimi, M.  
Functional responses of hindlimb circulation in aged normal  
and WHHL rabbits (93) 133  
Clifton, P.M., Wight, M.B. and Nestel, P.J.  
Is fat restriction needed with HMGCoA reductase inhibitor  
treatment? (93) 59  
Corsini, A., Mazzotti, M., Villa, A., Maggi, F.M., Bernini, F.,  
Romano, L., Romano, C., Fumagalli, R. and Catapano, A.L.  
Ability of the LDL receptor from several animal species to  
recognize the human apo B binding domain: studies with LDL  
from familial defective apo B-100 (93) 95  
Craig, W.Y. and Ledue, T.B.  
The effect of long term storage on serum Lp(a) levels (93) 261
- Daerr, W.H., Windler, E.T.E and Greten, H.  
Streptavidin binds to a 130-kDa protein from solubilized  
human skin fibroblast and Hep G 2 cell membranes (93) 161  
Davignon, J., see Blache, D. (93) 179
- de Reeder, E.G., see Slomp, J. (93) 25  
Duly, E., see Murphy, B.G. (93) 53  
Durrington, P.N., see Tames, F.J. (93) 237  
Durrington, P.N., see Winocour, P.H. (93) 83  
Dutkiewicz, T., see Wójcicki, J. (93) 7
- Ernst, E.  
Oral contraceptives, fibrinogen and cardiovascular risk (93) 1
- Fagin, J.A., see Khorsandi, M. (93) 115  
Fishbein, M.C., see Khorsandi, M. (93) 115  
Fleta, J., see Sarria, A. (93) 157  
Forrester, J.S., see Khorsandi, M. (93) 115  
Francis, S.E., Holt, C.M., Taylor, T., Gadsdon, P. and Angelini,  
G.D.  
Heparin and neointimal thickening in an organ culture of  
human saphenous vein (93) 155  
Fukazaki, H., see Tsunemitsu, M. (93) 229  
Fumagalli, R., see Corsini, A. (93) 95
- Gabaldón, M., Capdevila, C. and Zúñiga, A.  
Effect of spontaneous pathology and thrombin on leukocyte  
adhesion to rat aortic endothelium (93) 217  
Gadsdon, P., see Francis, S.E. (93) 155  
Giełdanowski, J., see Wójcicki, J. (93) 7  
Giner, A., see Sarria, A. (93) 157  
Gittenberger-de Groot, A.C., see Slomp, J. (93) 25  
Gonet, B., see Wójcicki, J. (93) 7  
Goto, K., see Miyachi, T. (93) 257  
Gotoda, T., see Inoue, I. (93) 245  
Grauls, G., see Span, A.H.M. (93) 41  
Greten, H., see Daerr, W.H. (93) 161  
Gruber, E., see Landi, A. (93) 17
- Harada, K., see Inoue, I. (93) 245  
Harland, J.O.E., see Winocour, P.H. (93) 71  
Henry, W., see Murphy, B.G. (93) 53  
Hoffman, R., Brook, G.J. and Aviram, M.  
Hypolipidemic drugs reduce lipoprotein susceptibility to  
undergo lipid peroxidation: in vitro and ex vivo studies (93)  
105  
Holl, L.G., see Tribble, D.L. (93) 189  
Holt, C.M., see Francis, S.E. (93) 155
- Inaba, T., see Inoue, I. (93) 245  
Inoue, I., Inaba, T., Motoyoshi, K., Harada, K., Shimano, H.,  
Kawamura, M., Gotoda, T., Oka, T., Shiomi, M., Watanabe,  
Y., Tsukada, T., Yazaki, Y., Takaku, F. and Yamada, N.  
Macrophage colony stimulating factor prevents the progres-

- sion of atherosclerosis in Watanabe heritable hyperlipidemic rabbits (93) 245
- Ishikawa, Y., see Tsunemitsu, M. (93) 229
- Ishola, M., see Winocour, P.H. (93) 83
- Italiano, G., see Cirillo, R. (93) 133
- Juzwiak, S., see Wójcicki, J. (93) 7
- Kadhubowska, D., see Wójcicki, J. (93) 7
- Kawamura, M., see Inoue, I. (93) 245
- Keller, L., see Landi, A. (93) 17
- Khorsandi, M., Fagin, J.A., Fishbein, M.C., Forrester, J.S. and Cersek, B.  
Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats (93) 115
- Kotze, M.J., see Kriek, J.A. (93) 165
- Krauss, R.M., see Tribble, D.L. (93) 189
- Kriek, J.A., Steyn, K., Weight, M.J., Kotze, M.J. and van Zyl, L.J.  
Response to treatment with simvastatin in a compound FH heterozygote (93) 165
- Kuhn, H., see Roux, S.P. (93) 123
- La Ville, A.E., see Vilella, E. (93) 145
- Laing, I., see Tames, F.J. (93) 237
- Laker, M.F., see Winocour, P.H. (93) 71
- Landi, A., Bihari-Varga, M., Keller, L., Mezey, Z. and Gruber, E.  
Elastase-type enzymes and their relation to blood lipids in atherosclerotic patients (93) 17
- Larraz, L., see Sarria, A. (93) 157
- Lasierra, M.P., see Sarria, A. (93) 157
- Ledue, T.B., see Craig, W.Y. (93) 261
- Lengsfeld, H., see Roux, S.P. (93) 123
- Lutton, C., see Ouguerram, K. (93) 201
- Mackness, M., see Winocour, P.H. (93) 83
- Mackness, M.I., see Tames, F.J. (93) 237
- Maggi, F.M., see Corsini, A. (93) 95
- Magot, T., see Ouguerram, K. (93) 201
- Marsal, S., see Vilella, E. (93) 145
- Masaki, T., see Miyauchi, T. (93) 257
- Masana, Ll., see Vilella, E. (93) 145
- Matsuda, M., see Miyauchi, T. (93) 257
- Mazzotti, M., see Corsini, A. (93) 95
- McCollum, C.N., see Blann, A.D. (93) 255
- McNamee, P., see Murphy, B.G. (93) 53
- Mezey, Z., see Landi, A. (93) 17
- Millar, J.P., see Winocour, P.H. (93) 71
- Miyauchi, T., Sugishita, Y., Matsuda, M., Sakai, H., Suzuki, N., Masaki, T. and Goto, K.  
Increased plasma concentration of endothelin-1 in cholesterol-fed rats (93) 257
- Morand, O.H., see Roux, S.P. (93) 123
- Moreno, L., see Sarria, A. (93) 157
- Motoyoshi, K., see Inoue, I. (93) 245
- Mukhin, D.N. and Prokazova, N.V.  
Neutral glycosphingolipid content and composition of cells from normal and atherosclerotic human aorta (93) 173
- Murphy, B.G., McNamee, P., Duly, E., Henry, W., Archbold, P. and Trinick, T.  
Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis (93) 53
- Nestel, P.J., see Clifton, P.M. (93) 59
- Oka, T., see Inoue, I. (93) 245
- Ouguerram, K., Magot, T. and Lutton, C.  
Metabolism of intestinal triglyceride-rich lipoproteins in the genetically hypercholesterolemic rat (RICO) (93) 201
- Poelmann, R.E., see Slomp, J. (93) 25
- Prokazova, N.V., see Mukhin, D.N. (93) 173
- Prosdocimi, M., see Cirillo, R. (93) 133
- Roda, L., see Sarria, A. (93) 157
- Romano, C., see Corsini, A. (93) 95
- Romano, L., see Corsini, A. (93) 95
- Roth, I., see Seifert, P.S. (93) 209
- Roux, S.P., Kuhn, H., Lengsfeld, H. and Morand, O.H.  
Effects of chronic aortic coarctation on atherosclerosis and arterial lipid accumulation in the Watanabe hereditary hyperlipidemic (WHHL) rabbit (93) 123
- Róziewska, L., see Wójcicki, J. (93) 7
- Sakai, H., see Miyauchi, T. (93) 257
- Samochowiec, L., see Wójcicki, J. (93) 7
- Sarria, A., Moreno, L., Fleta, J., Lasierra, M.P., Roda, L., Giner, A., Larraz, L. and Bueno, M.  
Immunoglobulins, complement components and lymphocyte subsets are related to plasma lipoproteins in healthy children (93) 157
- Seifert, P.S., Roth, I. and Zioncheck, T.F.  
The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation (93) 209
- Shimano, H., see Inoue, I. (93) 245
- Shiomii, M., see Inoue, I. (93) 245
- Simons, L.A.  
Dietary fish oils and Lp(a) (93) 169
- Slomp, J., van Munsteren, J.C., Poelmann, R.E., de Reeder, E.G., Bogers, A.J.J.C. and Gittenberger-de Groot, A.C.  
Formation of intimal cushions in the ductus arteriosus as a model for vascular intimal thickening. An immunohistochemical study of changes in extracellular matrix components (93) 25
- Span, A.H.M., Grauls, G., Bosman, F., van Boven, C.P.A. and Bruggeman, C.A.  
Cytomegalovirus infection induces vascular injury in the rat (93) 41
- Steyn, K., see Kriek, J.A. (93) 165
- Sugishita, Y., see Miyauchi, T. (93) 257
- Suzuki, N., see Miyauchi, T. (93) 257
- Takaku, F., see Inoue, I. (93) 245
- Tames, F.J., Mackness, M.I., Arrol, S., Laing, I. and Durrington, P.N.

- Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects (93) 237
- Taniguchi, T., see Tsunemitsu, M. (93) 229
- Taylor, T., see Francis, S.E. (93) 155
- Torbus-Lisiecka, B., see Wójcicki, J. (93) 7
- Tribble, D.L., Holl, L.G., Wood, P.D. and Krauss, R.M.  
Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size (93) 189
- Trinick, T., see Murphy, B.G. (93) 53
- Tsukada, T., see Inoue, I. (93) 245
- Tsunemitsu, M., Ishikawa, Y., Taniguchi, T., Fukazaki, H. and Yokoyama, M.  
Association of N-glycosylation of apolipoprotein B-100 with plasma cholesterol levels in Watanabe heritable hyperlipidemic rabbits (93) 229
- Turner, P.R., see Vilella, E. (93) 145
- van Boven, C.P.A., see Span, A.H.M. (93) 41
- van Munsteren, J.C., see Slomp, J. (93) 25
- Van Zyl, L.J., see Kriek, J.A. (93) 165
- Vilella, E., Balanyà, J., Masana, Ll., Marsal, S., La Ville, A.E. and Turner, P.R.  
Low density lipoprotein ligand-receptor interactions in normal healthy individuals characterized by their *Xba*I apolipoprotein B DNA polymorphism (93) 145
- Villa, A., see Corsini, A. (93) 95
- Watanabe, Y., see Inoue, I. (93) 245
- Weight, M.J., see Kriek, J.A. (93) 165
- Wesofowska, T., see Wójcicki, J. (93) 7
- Wight, M.B., see Clifton, P.M. (93) 59
- Windler, E.T.E., see Daerr, W.H. (93) 161
- Winocour, P.H., Durrington, P.N., Bhatagnar, D., Ishola, M., Mackness, M., Arrol, S. and Anderson, D.C.  
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia (93) 83
- Winocour, P.H., Harland, J.O.E., Millar, J.P., Laker, M.F. and Alberti, K.G.M.M.  
Microalbuminuria and associated cardiovascular risk factors in the community (93) 71
- Wira, D., see Wójcicki, J. (93) 7
- Wójcicki, J., Dutkiewicz, T., Giedanowski, J., Samochowiec, L., Barcew-Wiszniowska, B., Różewicka, L., Wira, D., Wesofowska, T., Torbus-Lisiecka, B., Gonet, B., Juzwiak, S. and Kadłubovska, D.  
Essential phospholipids modify immunological functions and reduce experimental atherosclerosis in rabbits (93) 7
- Wood, P.D., see Tribble, D.L. (93) 189
- Yamada, N., see Inoue, I. (93) 245
- Yazaki, Y., see Inoue, I. (93) 245
- Yokoyama, M., see Tsunemitsu, M. (93) 229
- Zioncheck, T.F., see Seifert, P.S. (93) 209
- Zúñiga, A., see Gabaldón, M. (93) 217

## Subject Index (Vol. 93)

- Afrikaner, (93) 165  
 Adherence, (93) 41  
 Aggregation, (93) 179  
 Anti-oxidants, (93) 105  
 Aortic endothelium, (93) 217  
 Apolipoprotein(a), (93) 53  
 Apolipoprotein B, (93) 237  
 Apolipoprotein B-100, (93) 95; (93) 229  
 Argyrophilic cells, (93) 217  
 Arterial wall injury, (93) 115  
 Aspirin, (93) 179  
 Atherosclerosis, (93) 41; (93) 105; (93) 123; (93) 133; (93) 157; (93) 173; (93) 209; (93) 257  
 Bezafibrate, (93) 83; (93) 105  
 Binding, (93) 145  
 Biotinylated lipoproteins, (93) 161  
 Blood lipids, (93) 17  
 Bradykinin, (93) 133  
 Cardiovascular disease, (93) 71  
 Cardiovascular risk, (93) 1  
 Cholesterol metabolism, (93) 201  
 Cholesterol, (93) 53; (93) 59; (93) 123; (93) 145; (93) 229  
 Cholesterol-fed rats, (93) 257  
 Cholestryler ester, (93) 201  
 Cholestramine, (93) 105  
 Chylomicrons, (93) 201  
 Cigarette smoking, (93) 179  
 Coagulation, (93) 1  
 Complement, (93) 157  
 Continuous ambulatory peritoneal dialysis (CAPD), (93) 53  
 Cytokine, (93) 245  
 Cytomegalovirus, (93) 41  
 Degradation, (93) 145  
 Density gradient ultracentrifugation, (93) 189  
 Diabetes, (93) 71  
 Diabetes mellitus, (93) 237  
 Diet, (93) 59  
 Ductus arteriosus, (93) 25  
 Elastase inhibitors, (93) 17  
 Elderly, (93) 71  
 Endothelin-1, (93) 257  
 Endothelium, (93) 41; (93) 179  
 Essential phospholipids, (93) 7  
 Experimental atherosclerosis, (93) 7  
 Extracellular matrix components, (93) 25  
 Familial hypercholesterolemia, (93) 165; (93) 237  
 Fibrinogen, (93) 1; (93) 71  
 Fish oils, (93) 169  
 Foam cell, (93) 245  
 Free cholesterol, (93) 189  
 Glycation, (93) 237  
 Glycosaminoglycans, (93) 25  
 Glycosphingolipids, (93) 173  
 Gradient gel electrophoresis, (93) 189  
 HDL, (93) 59  
 Healthy, (93) 157  
 Hemorheology, (93) 1  
 Heparin, (93) 155  
 High-fat diet, (93) 7  
 Hindlimb circulation, (93) 133  
 Hormones, (93) 1  
 Human aorta, (93) 173  
 Hypercholesterolemia, (93) 83; (93) 95; (93) 105; (93) 123; (93) 201  
 Hypertension, (93) 71; (93) 123  
 Hypertriglyceridemia, (93) 83; (93) 169  
 Hypophysectomy, (93) 115  
 Immune system, (93) 7  
 Immunoassay, (93) 261  
 Immunoglobulins, (93) 157  
 Inflammation, (93) 209  
 Insulin-like growth factor-I, (93) 115  
 Intima cells, (93) 173  
 Intimal thickening, (93) 25  
 Ischemic vascular disease, (93) 17  
 Kilham rat virus, (93) 217  
 LDL, (93) 59  
 LDL- (B/E) receptor, (93) 161  
 LDLR genes, (93) 165  
 Leukocyte adhesion, (93) 217  
 Ligand blotting, (93) 161  
 Lipid, (93) 209  
 Lipid accumulation, (93) 41; (93) 173  
 Lipid metabolism, (93) 7  
 Lipid peroxidation, (93) 189  
 Lipoprotein(a), (93) 53; (93) 169; (93) 261  
 Lipoprotein composition, (93) 83  
 Lipoprotein oxidation, (93) 105  
 Lipoproteins, (93) 71  
 Lipoproteins, (93) 157

- Low-density lipoprotein subfractions, (93) 189  
Low-density lipoprotein, (93) 237  
Lymph, (93) 201  
Lymphocyte subsets, (93) 157
- M-CSF, (93) 245  
Macrophage, (93) 245  
Microalbuminuria, (93) 71  
Monoclonal antibodies, (93) 95  
*Mycoplasma pulmonis*, (93) 217  
Myocardial infarction, (93) 17
- N-glycosylation, (93) 229  
N-linked sugar chain, (93) 229  
Neointimal proliferation, (93) 115
- Oral contraceptives, (93) 1  
Organ culture, (93) 155
- Persistent ductus arteriosus, (93) 25  
Phospholipids, (93) 123  
Plasma concentration, (93) 257  
Plasma lipids, (93) 179  
Platelet function, (93) 179  
Pravastatin, (93) 105
- Rabbit, (93) 7  
Rat, (93) 201  
Restriction fragments, (93) 145  
Risk factors, (93) 255
- Sendai virus, (93) 217  
Saphenous vein, (93) 155  
Scanning and transmission electron microscopy, (93) 133  
Serum elastase-type proteases, (93) 17  
Simvastatin, (93) 59; (93) 165  
Storage, (93) 261  
Streptavidin, (93) 161
- TBARS, (93) 189  
Thrombin, (93) 217  
Type 1 diabetes, (93) 83
- Vascular disease, (93) 255  
Very low density lipoproteins, (93) 201  
von Willebrand factor antigen, (93) 255
- Watanabe heritable hyperlipidemic (WHHL) rabbit, (93) 229; (93) 123; (93) 133; (93) 245